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INTRODUCTION
Prostate cancer (PCa) is a common malignancy and a leading cause of cancer death among men in the United States. Racial differences in PCa incidence and mortality are well documented. The incidence and mortality for PCa is about twofold higher in African-American (AA) in comparison with European-American (EA) men, with AA men experiencing among the highest rates worldwide [1] . African-American men have a 60% increased risk of developing prostate cancer, twice the risk of developing distant disease and twice the mortality relative to their European-American counterpart [2] . The disparity in PCa is believed to be a complex combination of socioeconomic factors, environment and genetics [3] . Genetic differences including mutation, loss or the amplification of different chromosomal regions may also play a major role in the disparity observed in prostate cancer incidence and mortality between AA and EA men.
Recent advances in genomic studies have identified several genes involved in pathways relevant to prostate cancer biology; in particular, a number of genes with alleles which differ in frequency between AA and EA have been proposed as a genetic cause or contributor to the increased risk of PCa in AA. Genes that are involved in the sex steroid hormones and components of their signaling and metabolic pathways has been extensively studied in relation to prostate cancer susceptibility and shown to differ in AA and EA populations [4] . To date, single-nucleotide polymorphisms (SNPs) identified on 8q24 is well documented as risk alleles for AA men with prostate cancer [5] . However, the risk variants are located in non-protein coding regions and the biological mechanisms underlying this association remain unclear.
In addition to the genomic defects associated with increased risk of prostate cancer, epigenetic defects such as DNA methylation changes and histone modifications are increasingly found to be associated with prostate disease prevalence. There is growing evidence to suggest that epigenetic DNA methylation changes affects gene expression in an age-dependent and tissue specific manner [6] . We have recently demonstrated that indeed CpG hypermethylation increases with age in the normal human prostate tissues [7] . Such age-dependent DNA methylation changes can alter cell physiology and possibly, predispose prostate cells to neoplastic transformation. Also in many cases, aberrant methylation precedes full-blown malignancy and can often be found in noncancerous tissues; in the prostate, hypermethylation of the GSTP1 CpG has been detected in PIA lesions [8] . DNA methylation occurs at CpG sites in the human genome and involves the addition of a methyl group to the 5'-carbon of cytosine, forming 5-methylcytosine (5-meC; [9, 10] ). Since the recognition that the GSTP1 CpG island was frequently hypermethylated in PCa, more than 40 genes have been reported to be targets of DNA hypermethylation-associated epigenetic gene silencing in PCa cells [11] . Ethnic group-related differences in CpG hypermethylation has also been identified for several genes. One study demonstrated that GSTP1 hypermethylation was significantly higher in PCa samples from AA men in comparison with EA and Asians [12] . Another study found higher frequency of hypermethylation of cell adhesion molecule (CD44) hypermethylation in prostate cancer tissues from AA in comparison to EA [13] suggesting that inactivation by CpG methylation may play a role in the disparity associated with prostate carcinogenesis. Our preliminary data demonstrate higher methylation of several genes in prostate tissue samples from AA in comparison with their EA counterparts [14] . The current literature suggests a complex mechanism of epigenetic regulation in prostate cancer including DNA methylation changes that can lead to either gene silencing or the activation of key regulatory genes in the disease pathway.
Underlying this aberrant DNA methylation is the accumulating body of data hinting that normal prostate cells may be subjected to a relentless barrage of genome-damaging stresses due to both exogenous and endogenous carcinogens, with damage accumulating over time and age. Thus aberrant epigenetic DNA methylation changes may represent the integration of environmental or lifestyle exposures and genetic predisposition to prostate cancer. Such events may differ between individuals belonging the same ethnic group or individuals belonging to different ethnic groups. Thus the elucidation of genome-wide DNA methylation changes in prostate tissues from different ethnic groups would contribute to our understanding of the molecular mechanisms underlying prostate cancer disparity and potentially lead to the identification of "ethnic sensitive" biomarkers for early disease detection. We know that there are different thresholds for AA versus EA men for PSA screening. Therefore other markers such as DNA methylated genes that can clarify such ethnic sensitive screening strategies would also be helpful. Furthermore, differential methylation changes could also lead to identification of potential novel therapeutic targets for prostate cancer treatment.
In this study we sought to investigate whether differential DNA methylation changes may represent an integration of lifestyle and genetic predisposing factors to create a more aggressive disease milieu in African American patients.
BODY
As outlined in our Statement of work, we seek to accomplish 3 main tasks during the 3 years of funding. We have made substantial progress at the end of this first year of Regulatory review of human subjects' research has been completed, including at the DOD and at Howard University and Johns Hopkins University. In year one of this project, we have developed a novel complex internal standard approach to correct for these biases and put the DNA methylation estimates on an absolute scale between 0 and 1 for all samples. This involves spiking each sample with a fully methylated complex internal standard and developing a model based approach to adjust for these confounding parameters in the signals obtained for this internal standard.
We have seen that the relationship of the number of reads at a given 150 bp window (the signal) is highly linearly related to the number of methylated CpGs (see Figure below) .
We can then understand this relationship for each sample and adjust for this effect in order to put the methylation estimates for each sample on the same scale. With this internal spike-in, we have developed the computational approach to build a multi-parameter model to quantitatively estimate the degree of methylation after parameterizing CpG content and other inherent sequence biases. This model is then used to predict the extent of methylation at each region of methylation identified by the MACS software across the entire genome. We have now validated this approach by comparing the DNA methylation estimates to other independent methodologies including the Infunium 450k
Methylation array platform. The advantage of our qMBD-seq approach with these newly developed computational methods is that we can obtain genome-wide methylation data without bias to specific regions. With this method in hand, we are now ready to compare DNA methylation levels between African American and European-American prostate cancer tissues in a genome-wide level.
Task 3:
Identify, process and isolate DNA from fresh frozen prostate tissues from EA and AA subjects as described I proposal (months 6 -12).
We have now identified fresh frozen tissue blocks from several European-American and African-American prostate cancer subjects. Many of these have now been sectioned and subjected to DNA isolation. We expect to complete these activities in the next two months.
Task 4:
Carry out genome-wide DNA methylation analyses on samples (months 12 -24).
Data collection for these samples using the qMBD-seq approach is already under way.
We expect to complete genome-wide analysis of DNA methylation of the EuropeanAmerican and African-American prostate cancer specimens in year two of the project.
In a parallel approach, we have examined the methylation status of Infunium 450K (0 -6 months). As described above, these tasks have been completed. with cholera toxin (2.5ng/ml); epidermal growth factor (10 ng/ml); insulin (5 ng/ml); hydrocortisone (100 pg/ml); phosphoethanolamine (0.005 mM); and selenious acid (45 nM). These cell lines were used to investigate the methylation frequencies as described in Task DNA isolation from a subset of these specimens has already begun. We expect to complete these activities in years 2-3 of the project. This task is now under way for genes previously known to show cancer specific DNA hypermethylation in prostate cancer. As novel markers are identified through the ongoing genome-wide efforts, we will validate these new markers in the large cohort of AA and EA prostate cancer specimens during years 2-3 of the project.
Task 5:
Explore the CpG island of 5' upstream regions based on their mRNA sequence by using Human BLAT Search engine (http://www.genome.ucsc.edu/cgi-bin/hgBlat) (months 12-13). These activities are now under way. They will be carried out for each novel biomarker that is discovered and prioritized through the genome-wide efforts. These activities are now underway. They will be carried out for each novel biomarker that is discovered and prioritized through the genome-wide efforts. derived from both African-American and European-American patients as described in task 2 above. We explored the CpG island using the Human BLAT search engine and designed bisulfite primers based on bisulfite-converted sequence from the CpG island. We will validate these new markers in the large cohort of AA and EA prostate cancer specimens during years 2-3 of the project.
KEY RESEARCH ACCOMPLISHMENTS:
 We have developed the qMBD-seq genome-wide DNA methylation technology as an approach that features the use of the methyl-binding domain of the MBD2
protein (MBD2-MBD) to bind and enrich methylated DNA fragments with high avidity and specificity. We have developed internal standards to obtain genomewide methylation data without bias to specific regions. This approach will overcome some of the signal biases and challenges in quantitative determination of DNA methylation and assessment of differential methylation across sample groups.
 We have used the illumina infunium 450K genome-wide methylation array to identify 25 novel methylated genes that are differentially methylated in primary 
CONCLUSION:
Our preliminary data using the Infunium 450K methylation array platform has demonstrated proof of principle that the quantification of methylation status by genomewide arrays can be collaborated by single-gene based analysis such as pyrosequencing.
Our on-going genome-wide methylation technology is the qMBD-Seq approach that features use of the methyl-binding domain of the MBD2 protein (MBD2-MBD) to bind and enrich methylated DNA fragments with high avidity and specificity. The advantage of our qMBD-sequencing approach over other genome-wide approaches is that we can obtain genome-wide methylation data without bias to specific regions, with this in mind we are now ready to compare DNA methylation levels between African-American and European-American prostate cancer tissues in a genome-wide level.
FUTURE WORK WILL FOCUS ON:
 CpG locus was validated in silico using an independent, publicly available methylome dataset from the Cancer Genome Atlas. The majority of these loci were informative particularly in the prostate cancer. Overall, cluster analysis showed gene set enriched in pathways including transcriptional modifications, apoptosis/autophagy, chromatin assembly, growth factor signaling, cell cycle regulation and oxidative-redox reaction. This study shows that CpG locus methylation arrays could reveal important biological differences in the epigenome between prostate cancer and non-malignant tissues and provide potential markers for disease detection and/or progression.
